Dishman Carbogen Amcis Limited provides contract development and manufacturing organization (CDMO) services for the pharmaceutical and healthcare industries worldwide. It operates through Integrated CDMO Platform and Marketable Molecules segments. The company offers cholesterol and vitamin D analogs; soft gel capsules and formulations; intermediate and active pharmaceutical ingredients (APIs) which cover specific therapeutic areas, such as anesthetics, and contrast media agents for diagnostics, ophthalmic treatments, laxatives, and organophosphate antidotes; ammonium and phosphonium; quats, phosphoranes, and wittig reagents; generic intermediates; cholesterol and lanolin-related products; sterile injectables; specialty chemicals and disinfectants, as well as hand and body wash, sanitizers, and antiseptic formulations. It also provides encapsulation and formulation capabilities; phase transfer catalysts; drug product, finished, and HiPo formulations; generic and highpotent APIs; Health and personal care solutions; and drug linkers and payloads. The company was founded in 1983 and is headquartered in Ahmedabad, India. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Research context
Dishman Carbogen Amcis Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Dishman Carbogen Amcis Limited is currently in a long term uptrend where the price is trading 34.2% above its 200 day moving average.
From a valuation standpoint, the stock is 81.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Dishman Carbogen Amcis Limited's total revenue sank by 13.6% to $5B since the same quarter in the previous year.
Its net income has dropped by 148.9% to $-161M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.3% to $2B since the same quarter in the previous year.
Based on the above factors, Dishman Carbogen Amcis Limited gets an overall score of 3/5.